Compass Therapeutics, Inc. · NASDAQ:CMPX

Compass Therapeutics — Investor Presentation (April 2025)

10 slides from Compass Therapeutics's investor presentation, Apr 1, 2025

  1. Slide 1: COMPANION-002 Data Disclosure Presentation

    COMPANION-002 Data Disclosure Presentation Nasdaq: CMPX April 1, 2025

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the

  3. Slide 3: Tovecimig: Bispecific with Compelling MOA (DLL4 x VEGF-A)

    Tovecimig: Bispecific with Compelling MOA (DLL4 x VEGF-A) VEGF-A Anti-VEGF-A MAb Disrupts tumor vessel formation VEGF/VEGF-R signaling (proven anti-angiogenic mechanism) Targets tumor DLL4 expression and Anti-DLL4 MAb alters perfusion in tumor vessels DLL4-Notch-1 signaling DLL4 (novel angiogenesis

  4. Slide 4: COMPANION-002: Phase 2/3 U.S. BTC Study

    COMPANION-002: Phase 2/3 U.S. BTC Study Registrational-intent study in patients who have received one prior line of therapy Study Treatment – 28 Day Cycles Follow Up Tovecimig + Paclitaxel n=111 Disease progression per Follow-up approx. RECIST v1.1, as confirmed by every 3 months Independent Central

  5. Slide 5: Tovecimig: Ongoing Phase 2/3 Summary - Primary Endpoint

    Tovecimig: Ongoing Phase 2/3 Summary - Primary Endpoint COMPANION-002 Study Tovecimig Paclitaxel (BTC) + Paclitaxel Intent-to-Treat Population n=111 n=57 Overall Response Rate (CR+PR) 19 (17.1%) 3 (5.3%) Two-Sided p-value p=0.031 Complete Response (CR) 1 (0.9%) 0 (0.0%) Best Partial Response (PR) 18

  6. Slide 6: Tovecimig: Top-line Ph 2/3 Activity in Patients with BTC (2L)

    Tovecimig: Top-line Ph 2/3 Activity in Patients with BTC (2L) Target Lesion (% change) Patients Paclitaxel Monotherapy Target Lesion (% change) Tovecimig Patients + Paclitaxel 6

  7. Slide 7: Tovecimig: Potential to Become Standard of Care in 2L BTC

    Tovecimig: Potential to Become Standard of Care in 2L BTC Median Progression Free Survival Line Program N ORR Median Overall Survival Months 0 2 4 6 8 10 12 14 First Line 7.2 m 12.8 m 1L Gem/Cis + Durv1 341 26.7% 6.5 m 12.7 m 1L Gem/Cis + Pembro2 533 28.7% Second Line 81 5.3 m BSC 0% 2L ABC-063 81 4

  8. Slide 8: Significant Unmet Needs in Current Treatments for BTC

    Significant Unmet Needs in Current Treatments for BTC Currently Approved SoC Unmet Needs 1L durvalumab (TOPAZ1)1 2-year OS of 24.9%1 Gem/Cis + pembrolizumab (KN-966)2 Majority of patients will progress Addressable opportunity for tovecimig in the 2L setting ~85% of 2L FOLFOX chemotherapy3: patients

  9. Slide 9: Incidence of BTC is Significant and Not Fully Appreciated

    Incidence of BTC is Significant and Not Fully Appreciated Liver Epidemiology-based Claims-based Cancer site Approach (SEER) Approach (ICD) Intrahepatic Liver & intrahepatic 15%2 of 42,2401 --- Perihilar bile duct Gallbladder & other 12,6101 --- Extrahepatic biliary Distal Other & unspecific Gallblad

  10. Slide 10: Key Anticipated Milestones

    Key Anticipated Milestones 2025 Q1 Q2 Q3 Q4 Q1 2025 17.1% ORR (p=0.031) Q4 2025 Tovecimig BTC Initiated Ph 2 IST Top-line Ph 2/3 Data Ph 2/3 Data (2L) (1L) (2L) PFS, OS, DoR Mid-2025 Tovecimig CRC Initiate Ph 2 (DLL4 biomarker) Mid-2025 CTX-471 Initiate Ph 2 (NCAM biomarker) H1 2025 H2 2025 CTX-8371

Compass Therapeutics — Investor Presentation (April 2025) on 6ix